Centre hospitalier universitaire de Tivoli Institut medical des Mutualites socialistes
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Centre hospitalier universitaire de Tivoli Institut medical des Mutualites socialistes in La Louviere, clinical research in Cardiology focuses on cardiovascular diseases such as atrial fibrillation and acute ischemic stroke with high-risk transient ischemic attack. These studies are designed to assess whether new treatments can better prevent serious clot-related events and improve protection against stroke.
- Research on preventing cardioembolic events in people with atrial fibrillation
- Studies evaluating protection after acute ischemic stroke or high-risk transient ischemic attack
- Trials comparing new approaches with established therapy or placebo to test effectiveness in stroke prevention
This work brings together prevention-focused research aimed at reducing the risk of future neurological and cardiovascular complications.
Female Urogenital Diseases and Pregnancy Complications
The site also supports research in female urogenital diseases, particularly endometriosis and its related pain. These trials are exploring new ways to relieve pelvic pain and to better understand the safety and tolerability of emerging treatments for women living with moderate to severe symptoms.
- Studies targeting endometriosis-related pain
- Evaluation of treatment options intended to reduce overall pelvic pain
- Research focused on the safety and tolerability of a new therapy for symptomatic relief
This area of research reflects a broader effort to improve day-to-day quality of life for patients affected by chronic gynecologic pain.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 34 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Eli Lilly & Co.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre hospitalier universitaire de Tivoli Institut medical des Mutualites socialistes
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 34 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aticaprant | 2 | Unknown | 2024-11-14 | 2024-12-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.